Celltrion secures FDA approval for bone disease biosimilars
Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug Administration.
Stoboclo is approved for treating postmenopausal osteoporosis in women, while Osenvelt is indicated for the prevention of skeletal-related complications in cancer patients with bone metastases and for giant cell tumors of bone. Both products have been approved for all indications covered by the original reference drugs in the US.
Prolia and Xgeva recorded approximately $6.59 billion combined in global sales in 2023, with the US market alone accounting for two-thirds of that at $4.39 billion.
Celltrion plans to launch Stoboclo and Osenvelt in the US market as early as this year, following the completion of a patent settlement agreement with the original drug developer.
In November, Celltrion became the first company in Korea to obtain approval for these biosimilars, ahead of competing products. It also secured approval from the European Commission last month, accelerating its efforts to expand sales in major global markets.
Celltrion has been making aggressive moves to broaden its treatment portfolio, gaining approval for biosimilars for autoimmune diseases, oncology, ophthalmology and bone disease across key global markets. So far this year, the company has obtained three product approvals in the US and four in Europe, totaling seven across both markets.
The company last year already surpassed its goal of establishing an 11-product portfolio in Korea by 2025. It recently met the same goal in Europe.
"Our recent approvals in major global markets reaffirm our in-house biosimilar development capabilities," a Celltrion official said. "We will focus on completing the remaining regulatory approvals for our pipeline products while ensuring the rapid market penetration of approved products to drive revenue growth."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
KITA steps up EU outreach, calls for regulatory easing
Yoon Jin-sik, chair of the Korea International Trade Association, stepped up trade outreach activities with key European Union officials, conveying the challenges Korean companies face due to trade and regulatory hurdles. During Yoon's visit to Brussels from Friday to Tuesday, he held meetings with several senior officials at the European Parliament and the European Commission, including Cesar Luena, chair of the delegations for relations with the Korean Peninsula, Marie-Pierre Vedrenne of committee on international trade, Dan Barna of the committee on foreign affairs and Maria Martin-Prat, deputy director general of the directorate general for trade at the European Commission. Yoon expressed concerns over the EU's moves to tighten internal market protections in response to recent US tariff policies, urging that Korean companies, which are key contributors to core EU industries, receive equal treatment as EU-based firms, according to KITA. He also delivered a position paper to the European Commission authorities, pointing out difficulties Korean companies face under the EU's Carbon Border Adjustment Mechanism, despite the expectation that the second Ursula von der Leyen administration may ease trade-related regulations. Yoon pointed out difficulties with carbon emissions verification and requested the expansion of authorized verifiers, as well as the recognition of carbon emissions verification exports issued by Korean institutions. Under the CBAM, the EU's carbon tax on imported goods, companies importing carbon-intensive products into the EU have to purchase and submit certificates starting in 2026. Under this rule, companies have to receive verification by an external body on their emissions data. KITA's position paper emphasized that many Korean firms are expressing difficulties due to a limited number of verification bodies and excessively high costs. Some EU-based agencies have demanded tens of millions of won from Korean firms for emissions verification. In response, Martin-Prat said the EU would pay more attention to reducing regulatory and nontariff barriers for Korean companies operating in the region, according to KITA. KITA also organized the first-ever EU-Korea Networking Day, co-hosted with the Korean Embassy in Belgium and the EU on Tuesday. The event drew over 150 attendees, including EU policymakers and Korean business leaders, to discuss economic cooperation. 'With the global trade environment facing upheaval, no country or economic zone can respond to these challenges alone,' Yoon was quoted as saying. 'As cooperation between like-minded allies, such as Korea and the EU, becomes even more important, we will actively pursue trade support activities in Europe.'
Korea Herald
3 days ago
- Korea Herald
Korean biopharma firms gear up for record presence at BIO USA 2025
Samsung Biologics to showcase CDMO scale-up, digital transformation with largest Korean booth Korean pharmaceutical and biotechnology companies are gearing up for a strong presence at the 2025 BIO International Convention (BIO USA), one of the world's largest biopharma exhibitions, which will take place in Boston starting June 16. Organized annually by the Biotechnology Innovation Organization, BIO USA rotates among major US biotech hubs and serves as a premier global platform for industry leaders to explore strategic partnerships and collaborations. This year's convention, held under the theme 'The World Can't Wait,' will run from June 16 to 19 at the Boston Convention & Exhibition Center. The event is expected to draw more than 9,000 companies from 88 countries and over 20,000 professionals from across the biopharma sector. Roughly 80 Korean companies and organizations will participate by setting up booths. Samsung Biologics Samsung Biologics, one of the largest exhibitors, will mark its 13th consecutive year taking part in the event. It will set up a 167-square-meter booth at the entrance of the exhibition hall — the area with the highest foot traffic — to maximize visibility and draw visitor attention. The booth will showcase the company's expanding contract development and manufacturing organization capabilities through high-tech features such as an LED display wall and interactive touchscreens. These elements are designed to communicate Samsung's advanced service offerings with a strong emphasis on digital transformation in biopharma. Highlights will include a comprehensive look at Samsung Biologics' latest advancements, such as the recent launch of its fifth manufacturing plant, boosting its total production capacity to 784,000 liters — among the highest in the world. The company will also spotlight its capabilities in multi-specific antibody development, its newly introduced antibody-drug conjugate services and AI-driven operational systems, all of which support its goal of becoming a global top-tier CDMO. Other leading Korean CDMO and CMO firms — Celltrion, SK Biopharmaceuticals and Lotte Biologics — will also be attending, competing for new contracts against major players from the US, China and Japan. Celltrion, participating for the 16th year, will operate its own booth to promote products and engage with potential partners, while SK Biopharmaceuticals plans to focus on increasing global brand recognition through a series of high-level business development meetings. Lotte Biologics will showcase its ADC production facilities at the Syracuse Bio Campus and unveil the development roadmap for its Songdo Bio Campus Plant 1, scheduled to begin commercial operations in 2027. Although Daewoong Pharmaceutical and Hanmi Pharmaceutical will not operate a booth at the event, they will participate through business meetings, aiming to strengthen their global presence by showcasing ongoing research and development efforts in new drug discovery. The Cha Vaccine Institute will use the event to promote its shingles (CVI-VZV-001) and hepatitis B (CVI-HBV-002) vaccines, focusing on licensing and joint development opportunities. The institute aims to build partnerships across Southeast Asia, the Middle East, Europe and Latin America to explore co-development and tech transfer prospects. The Cha Vaccine Institute will also participate in the company presentation sessions and the Korea Pavilion pitching event, where it will outline its research pipelines and market strategies. 'We will introduce our proprietary adjuvant platform and vaccine development capabilities at BIO USA, aiming to turn this exposure into real business outcomes,' said Yeom Jeong-seon, CEO of the Cha Vaccine Institute. Meanwhile, Korea BIO will play a significant role at the convention. The Korea Pavilion will feature a record 51 Korean companies, and Korea BIO will facilitate discussions with the US BIO association on key issues, including customs regulations, drug pricing and supply chain resilience, while also providing a partnering platform for domestic companies. According to an industry insider, Korea stands to benefit significantly from shifting global dynamics at this year's BIO USA. 'As US-China tensions reshape the global biotech supply chain, Korean firms that can quickly adapt to geopolitical shifts are well-positioned to secure major deals. Their strong technological base and aggressive manufacturing scale-up efforts make them attractive alternatives to Chinese firms facing regulatory hurdles, potentially positioning Korea as a central beneficiary in the new global order,' the official said, on condition of anonymity.
Korea Herald
01-06-2025
- Korea Herald
Trump plans 50% tariffs on steel and aluminum
WEST MIFFLIN, Pennsylvania (Reuters) — US President Donald Trump said he planned to increase tariffs on imported steel and aluminum to 50 percent from 25 percent, ratcheting up pressure on global steel producers and deepening his trade war. "We are going to be imposing a 25 percent increase. We're going to bring it from 25 percent to 50 percent — the tariffs on steel into the United States of America, which will even further secure the steel industry in the United States," he said at a rally in Pennsylvania. The doubling of steel and aluminum levies intensifies Trump's global trade war and came just hours after he accused China of violating an agreement with the US to mutually roll back tariffs and trade restrictions for critical minerals. Trump announced the higher tariffs just outside Pittsburgh, where he was talking up an agreement between Nippon Steel and US Steel. Trump said the $14.9 billion deal, like the tariff increase, will help keep jobs for steel workers in the US. He later posted on social media that the increased tariff would also apply to aluminum products and that it would take effect Wednesday. Shares of steelmaker Cleveland-Cliffs surged 26 percent after the market close as investors bet the new levies will help its profits. The announcement drew harsh reactions from US trading partners around the world. Canada's Chamber of Commerce quickly denounced the tariff hike as "antithetical to North American economic security." "Unwinding the efficient, competitive and reliable cross-border supply chains like we have in steel and aluminum comes at a great cost to both countries," Candace Laing, president of the chamber, said in a statement. Canada's United Steelworkers union called the move a direct attack on Canadian industries and workers. The European Commission said Saturday that Europe was prepared to retaliate. "This decision adds further uncertainty to the global economy and increases costs for consumers and businesses on both sides of the Atlantic," a European Commission spokesperson said. "The EU is prepared to impose countermeasures, including in response to the latest US tariff increase." Australia's center-left government also condemned the tariff increase, with Trade Minister Don Farrell calling it "unjustified and not the act of a friend." Trump spoke at US Steel's Mon Valley Works, a steel plant that symbolizes both the one-time strength and the decline of US manufacturing power as the Rust Belt's steel plants and factories lost business to international rivals. Closely contested Pennsylvania is also a major prize in presidential elections. The US is the world's largest steel importer, excluding the European Union, with a total of 26.2 million tons of imported steel in 2024, according to the Department of Commerce. As a result, the new tariffs will likely increase steel prices across the board, hitting industry and consumers alike. Steel and aluminum tariffs were among the earliest put into effect by Trump when he returned to office in January. The tariffs of 25 percent on most steel and aluminum imported to the US went into effect in March, and he had briefly threatened a 50 percent levy on Canadian steel but ultimately backed off. Under the so-called Section 232 national security authority, the import taxes include both raw metals and derivative products as diverse as stainless steel sinks, gas ranges, air conditioner evaporator coils, horseshoes, aluminum frying pans and steel door hinges. The 2024 import value for the 289 product categories came to $147.3 billion with nearly two-thirds aluminum and one-third steel, according to Census Bureau data retrieved through the US International Trade Commission's Data Web system. By contrast, Trump's first two rounds of punitive tariffs on Chinese industrial goods in 2018 during his first term totaled $50 billion in annual import value.
